Spinach® rose to 8th place in the pre-roll category, capturing 2.5% market share in Q1 2023, up from 1.4% in Q4 20221

More:
Cronos Bolsters its Spinach® Infused Pre-roll Portfolio with CBG, CBC and CBN

Montrouge, France, April 12, 2023

Link:
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

Continue reading here:
Nkarta to Participate at Upcoming Investor Conferences

Anika Continues to Expand Addressable Market for Tactoset Injectable Bone Substitute with Additional 510(k) Clearance from FDA  Marketscreener.com

Read the original here:
Anika Continues to Expand Addressable Market for Tactoset Injectable Bone Substitute with Additional 510(k) Clearance from FDA - Marketscreener.com

MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023  Marketscreener.com

Continued here:
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 -...

Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent Data-Driven Technology Platform and AI Learning Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent Data-Driven Technology Platform and AI Learning

Read more:
OMNIMED™ Announces Integration of SmartOR™ Into Axis Research & Technologies Facilities

Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal Models

Link:
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead...

MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today provided a corporate update which includes entering into a new credit facility with investment affiliates managed by SLR Capital Partners, LLC (“SLR”) and providing Greenbrook TMS (“Greenbrook”) with a promissory note as part of an updated TMS device supply agreement.

Here is the original post:
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions

Read this article:
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio

View post:
Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to...

FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro.

Continue reading here:
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

FORT WORTH, TX, April 04, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that it has received 510(k) clearance for BIASURGE™ Advanced Surgical Solution (“BIASURGE™").

See more here:
Sanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical Solution

The Company strengthens its analytical R&D capabilities,to better support its customers operating in the CDMO and Generics market.

Read more:
Dipharma expands its Italian R&D Center to increase its analytical services

Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston on April 04, 2023. The title of her presentation will be “Case Study Spotlight: Introducing Innovations at Each Step of TCR Therapy Development”.

Go here to read the rest:
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American Academy of Neurology (AAN) conference in Boston, MA.

See the original post here:
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the original here:
Mendus announces request for conversion of convertible bonds by Negma Group

PRESS RELEASE

Link:
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral...

TORONTO, April 04, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Clinical Trial Supply New England 2023, April 5-6 in Boston, Massachusetts.

See the article here:
Axiom Exhibiting at Clinical Trial Supply New England 2023

MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations, patient advocacy, medical communications, managed markets, and naming and branding. Formally President of the US Public Relations Group at Syneos Health Communications, Jeanine has been with the organization for more than a decade and has more than 20 years of industry experience.

Continue reading here:
Syneos Health Names Jeanine O’Kane as Communications President

JENA, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).

Excerpt from:
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients